




## References

1. Becnel MR, Horowitz SB, Thomas SK, et al. Descriptive analysis of isatuximab use following prior daratumumab in patients with relapsed/refractory multiple myeloma. *Blood*. 2020;138(Suppl 1):20-21. <https://doi.org/10.1182/blood-2020-140526>
2. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study. *Lancet*. 2021;398(10297):314-324.
3. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. *N Engl J Med*. 2019;381(8):727-738.
4. Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. *N Engl J Med*. 2022;387(24):2232-2244.
5. Janssen Research & Development, LLC. A study of teclistamab with other anticancer therapies in participants with multiple myeloma (MajesTEC-2). Updated April 13, 2023. <https://clinicaltrials.gov/ct2/show/NCT04722146>
6. Janssen Research & Development, LLC. A study of teclistamab in combination with daratumumab subcutaneously (SC) (Tec-Dara) versus daratumumab SC, pomalidomide, and dexamethasone (DPd) or daratumumab SC, bortezomib, and dexamethasone (DvD) in participants with relapsed or refractory multiple myeloma (MajesTEC-3). Updated April 12, 2023. <https://clinicaltrials.gov/ct2/show/NCT05083169>
7. European Myeloma Network. Daratumumab, VELCADE (bortezomib), lenalidomide and dexamethasone compared to VELCADE, lenalidomide and dexamethasone in subjects with previously untreated multiple myeloma (Perseus). Updated September 27, 2022. <https://www.clinicaltrials.gov/ct2/show/NCT03710603>
8. Pfizer. MagnetisMM-3: Study of elranatamab (PF-06863135) monotherapy in participants with multiple myeloma who are refractory to at least one PI, one IMiD and one anti-CD38 mAb. Updated April 6, 2023. <https://clinicaltrials.gov/ct2/show/NCT04649359>
9. Hoffmann-La Roche. A study evaluating the efficacy and safety of cevostamab in prior B cell maturation antigen (BCMA)-exposed participants with relapsed/refractory multiple myeloma (CAMMA 2). Updated April 12, 2023. <https://clinicaltrials.gov/ct2/show/NCT05535244>
10. Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: A review. *JAMA*. 2022;327(5):464-477.
11. Davis J, McGann M, Shockley A, Hashmi H. Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma. *Expert Rev Hematol*. 2022;15(6):473-475.
12. Delimpasi S, Mateos MV, Auner HW, et al. Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: subgroup analysis from the BOSTON study. *Am J Hematol*. 2022;97(3):E83-E86.

## Clinical Compendium:

# A Critical Update on Therapy Selection, Sequencing, and Toxicity Management of Novel Therapies for Multiple Myeloma



13. Djebbari F, Poynton M, Sangha G, et al. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series. *Hematology*. 2022;27(1):204-207.
14. Dimopoulos MA, Richardson P, Lonial S. Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma. *Clin Lymphoma Myeloma Leuk*. 2022;22(7):460-473.
15. Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2021;22(11):1582-1596.
16. Gavriatopoulou M, Chari A, Chen C, et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. *Leukemia*. 2020;34(9):2430-2440.
17. Goldschmidt H, Mai EK, Bertsch U, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. *Lancet Haematol*. 2022;9(11):e810-e821.
18. Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. *Lancet*. 2020;396(10262):1563-1573.
19. Gupta VA, Barwick BG, Matulis SM, et al. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. *Blood*. 2021;137(26):3604-3615.
20. Hashmi H, Shockley A, Davis JA. "Save the day with a Stem Cell Rescue": Use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy. *Bone Marrow Transplant*. 2022;57(3):504-506. doi:10.1038/s41409-022-01570-4
21. Kaufman JL, Gasparetto C, Schjesvold FH, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. *Am J Hematol*. 2021;96(4):418-427.
22. Kumar SK, Dimopoulos MA, Kastiris E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study. *Leukemia*. 2017;31(11):2443-2448.
23. Logue JM, Peres LC, Hashmi H, et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. *Blood Adv*. 2022;6(24):6109-6119.
24. Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial. *Lancet*. 2020;395(10218):132-141.
25. Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial. *Lancet*. 2021;397(10292):2361-2371.
26. Moreau P, Garfall AL, van de Donk NWJ, et al. Teclistamab in relapsed or refractory multiple myeloma. *N Engl J Med*. 2022;387(6):495-505.

## Clinical Compendium:

# A Critical Update on Therapy Selection, Sequencing, and Toxicity Management of Novel Therapies for Multiple Myeloma



27. Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. *Lancet Oncol.* 2021;22(3):e105-e118.
28. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. *N Engl J Med.* 2021;384(8):705-716.
29. National Comprehensive Cancer Center. Multiple Myeloma. Version 3.2023. Updated December 8, 2022. Accessed February 28, 2023. [https://www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf)
30. Nooka AK, Joseph NS, Kaufman JL, et al. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. *Cancer.* 2019;125(17):2991-3000.
31. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report from International Myeloma Working Group. *J Clin Oncol.* 2015;33(26):2863-2869.
32. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. *Blood.* 2010;116(5):679-686.
33. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. *Blood.* 2020;136(8):936-945.